Eric Coldwell
Stock Analyst at Robert W. Baird
(4.57)
# 979
Out of 5,051 analysts
797
Total ratings
58.1%
Success rate
7.4%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Reiterated: Buy | $291 → $334 | $301.86 | +10.65% | 72 | Sep 25, 2026 | |
| AHCO AdaptHealth | Reiterated: Buy | $10 → $9 | $6.14 | +46.58% | 43 | Sep 17, 2026 | |
| ACH Accendra Health | Downgraded: Hold | $6 → $1.5 | $0.3905 | +284.12% | 73 | Aug 11, 2026 | |
| COR Cencora | Reiterated: Buy | $339 → $370 | $325.06 | +13.83% | 75 | Aug 6, 2026 | |
| MCK McKesson | Reiterated: Buy | $941 → $1,015 | $955.76 | +6.20% | 78 | Aug 6, 2026 | |
| MDLN Medline | Reiterated: Buy | $45 → $42 | $35.76 | +17.45% | 4 | Aug 6, 2026 | |
| ICLR ICON Public Limited Company | Reiterated: Buy | $186 → $194 | $164.40 | +18.00% | 71 | Jul 31, 2026 | |
| LH Labcorp Holdings | Reiterated: Buy | $334 → $352 | $315.52 | +11.56% | 74 | Jul 31, 2026 | |
| FTRE Fortrea Holdings | Reiterated: Buy | $20 → $23 | $21.00 | +9.52% | 15 | Jul 30, 2026 | |
| IQV IQVIA Holdings | Reiterated: Buy | $249 → $287 | $262.21 | +9.45% | 68 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $236 → $255 | $232.63 | +9.62% | 61 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $547 → $624 | $620.05 | +0.64% | 60 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $252 → $248 | $238.08 | +4.17% | 69 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $110 | $87.74 | n/a | 28 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $23 → $22 | $5.07 | n/a | 6 | May 9, 2014 |
Charles River Laboratories International
Sep 25, 2026
Reiterated: Buy
Price Target: $291 → $334
Current: $301.86
Upside: +10.65%
AdaptHealth
Sep 17, 2026
Reiterated: Buy
Price Target: $10 → $9
Current: $6.14
Upside: +46.58%
Accendra Health
Aug 11, 2026
Downgraded: Hold
Price Target: $6 → $1.5
Current: $0.3905
Upside: +284.12%
Cencora
Aug 6, 2026
Reiterated: Buy
Price Target: $339 → $370
Current: $325.06
Upside: +13.83%
McKesson
Aug 6, 2026
Reiterated: Buy
Price Target: $941 → $1,015
Current: $955.76
Upside: +6.20%
Medline
Aug 6, 2026
Reiterated: Buy
Price Target: $45 → $42
Current: $35.76
Upside: +17.45%
ICON Public Limited Company
Jul 31, 2026
Reiterated: Buy
Price Target: $186 → $194
Current: $164.40
Upside: +18.00%
Labcorp Holdings
Jul 31, 2026
Reiterated: Buy
Price Target: $334 → $352
Current: $315.52
Upside: +11.56%
Fortrea Holdings
Jul 30, 2026
Reiterated: Buy
Price Target: $20 → $23
Current: $21.00
Upside: +9.52%
IQVIA Holdings
Jul 29, 2026
Reiterated: Buy
Price Target: $249 → $287
Current: $262.21
Upside: +9.45%
Jul 24, 2026
Reiterated: Hold
Price Target: $236 → $255
Current: $232.63
Upside: +9.62%
Jul 24, 2026
Reiterated: Hold
Price Target: $547 → $624
Current: $620.05
Upside: +0.64%
May 1, 2026
Reiterated: Buy
Price Target: $252 → $248
Current: $238.08
Upside: +4.17%
Apr 18, 2022
Reiterated: Hold
Price Target: $110
Current: $87.74
Upside: n/a
May 9, 2014
Rated: Buy
Price Target: $23 → $22
Current: $5.07
Upside: n/a